{"id":7006,"date":"2009-09-17T13:20:00","date_gmt":"2009-09-17T13:20:00","guid":{"rendered":"http:\/\/www.pharma-mkting.com\/fda-reads-my-blog-declares-latisse-web\/"},"modified":"2019-02-21T01:22:37","modified_gmt":"2019-02-21T01:22:37","slug":"fda-reads-my-blog-declares-latisse-web","status":"publish","type":"post","link":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/fda-reads-my-blog-declares-latisse-web\/","title":{"rendered":"FDA Reads My Blog: Declares Latisse Web Site Misleading"},"content":{"rendered":"

On September 10, 2009, the FDA sent Allergan a notice that its Latisse Web site was misleading (see “FDA Says Allergan’s Web Site for Eyelash Thickener Is Misleading<\/a>“). The letter states:<\/p>\n

“the Division of Drug Marketing, Advertising, and Communications (DDMAC) has reviewed the \u201cFAQs\u201d and \u201cAbout Safety\u201d pages of a consumer website and a \u201cLaunch display timeline\u201d (timeline) (APC36ON09) for LatisseTM (bimatoprost ophthalmic solution) 0.03% (Latisse) submitted by Allergan, Inc. (Allergan) under cover of Form FDA-2253. These promotional materials are misleading because they omit and minimize risks associated with Latisse<\/b>. Thus, the website and timeline misbrand Latisse in violation of the Federal Food, Drug, and Cosmetic Act…” [my emphasis]<\/p>\n

Latisse is Allergan’s product approved for hypotrichosis, a term dermatologists use to describe a condition of no hair growth. Allergan markets Latisse for increasing the growth of eyelashes. <\/p>\n

In a previous post dated June 1, 2009 — “Will Latisse Turn Brooke Shields’ Blue Eyes Brown?<\/a>” — I noted that in the “About Safety” page of the Latisse web site, Allergan stated:<\/p>\n

“Increased brown iris pigmentation has occurred when similar medications were instilled directly into the eye to treat elevated intraocular pressure\/glaucoma. Although iris pigmentation was not reported in clinical studies with LATISSE\u2122, patients should be advised about the potential for increased brown iris pigmentation which is likely to be permanent.”<\/p>\n

I commented: When Allergan says “similar medications,” it really should have said “this medication” because Latisse is just another name for Lumigan, Allergan’s anti-glacoma drug. Both are (bimatoprost ophthalmic solution) 0.03%.<\/b><\/p>\n

FDA, in its letter to Allergan, said (click on image to enlarge and read):<\/p>\n

<\/a><\/div>\n

\nOf course, I conclude from this that FDA reads Pharma Marketing Blog. Maybe it has also read my post about organic search “ads” (see “Are Organic Search Results Next on FDA’s Chopping Block?<\/a>“).<\/p>\n","protected":false},"excerpt":{"rendered":"

On September 10, 2009, the FDA sent Allergan a notice that its Latisse Web site was misleading (see “FDA Says Allergan’s Web Site for Eyelash Thickener Is Misleading“). The letter states: “the Division of Drug Marketing, Advertising, and Communications (DDMAC) has reviewed the \u201cFAQs\u201d and \u201cAbout Safety\u201d pages of a consumer website and a \u201cLaunch […]<\/p>\n","protected":false},"author":2,"featured_media":9589,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12],"tags":[89,243,527,44,902],"topic":[],"acf":[],"yoast_head":"\nFDA Reads My Blog: Declares Latisse Web Site Misleading - Pharma Marketing Network<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/fda-reads-my-blog-declares-latisse-web\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Reads My Blog: Declares Latisse Web Site Misleading - Pharma Marketing Network\" \/>\n<meta property=\"og:description\" content=\"On September 10, 2009, the FDA sent Allergan a notice that its Latisse Web site was misleading (see “FDA Says Allergan’s Web Site for Eyelash Thickener Is Misleading“). The letter states: “the Division of Drug Marketing, Advertising, and Communications (DDMAC) has reviewed the \u201cFAQs\u201d and \u201cAbout Safety\u201d pages of a consumer website and a \u201cLaunch […]\" \/>\n<meta property=\"og:url\" content=\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/fda-reads-my-blog-declares-latisse-web\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Marketing Network\" \/>\n<meta property=\"article:published_time\" content=\"2009-09-17T13:20:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2019-02-21T01:22:37+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-content\/uploads\/2009\/09\/FDALatisseStatement1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"400\" \/>\n\t<meta property=\"og:image:height\" content=\"140\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pharma Guy\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pharma Guy\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/fda-reads-my-blog-declares-latisse-web\/\",\"url\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/fda-reads-my-blog-declares-latisse-web\/\",\"name\":\"FDA Reads My Blog: Declares Latisse Web Site Misleading - Pharma Marketing Network\",\"isPartOf\":{\"@id\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#website\"},\"datePublished\":\"2009-09-17T13:20:00+00:00\",\"dateModified\":\"2019-02-21T01:22:37+00:00\",\"author\":{\"@id\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#\/schema\/person\/763fc249c59c91ce203db612d81a75a1\"},\"breadcrumb\":{\"@id\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/fda-reads-my-blog-declares-latisse-web\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/fda-reads-my-blog-declares-latisse-web\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/fda-reads-my-blog-declares-latisse-web\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA Reads My Blog: Declares Latisse Web Site Misleading\"}]},{\"@type\":\"WebSite\",\"@id\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#website\",\"url\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/\",\"name\":\"Pharma Marketing Network\",\"description\":\"Pharma Marketing Network\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#\/schema\/person\/763fc249c59c91ce203db612d81a75a1\",\"name\":\"Pharma Guy\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#\/schema\/person\/image\/\",\"url\":\"http:\/\/2.gravatar.com\/avatar\/87853617a5e31233716811d09cdefdf7?s=96&d=identicon&r=g\",\"contentUrl\":\"http:\/\/2.gravatar.com\/avatar\/87853617a5e31233716811d09cdefdf7?s=96&d=identicon&r=g\",\"caption\":\"Pharma Guy\"},\"description\":\"Pharmaguy\u2122 is a \u201cconstructive critic\u201d of pharma marketing and publishes commentary on the Pharma Marketing Blog and on Scoop.it.\",\"url\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/author\/ehs-pharmaguy\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FDA Reads My Blog: Declares Latisse Web Site Misleading - Pharma Marketing Network","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/fda-reads-my-blog-declares-latisse-web\/","og_locale":"en_US","og_type":"article","og_title":"FDA Reads My Blog: Declares Latisse Web Site Misleading - Pharma Marketing Network","og_description":"On September 10, 2009, the FDA sent Allergan a notice that its Latisse Web site was misleading (see “FDA Says Allergan’s Web Site for Eyelash Thickener Is Misleading“). The letter states: “the Division of Drug Marketing, Advertising, and Communications (DDMAC) has reviewed the \u201cFAQs\u201d and \u201cAbout Safety\u201d pages of a consumer website and a \u201cLaunch […]","og_url":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/fda-reads-my-blog-declares-latisse-web\/","og_site_name":"Pharma Marketing Network","article_published_time":"2009-09-17T13:20:00+00:00","article_modified_time":"2019-02-21T01:22:37+00:00","og_image":[{"width":400,"height":140,"url":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-content\/uploads\/2009\/09\/FDALatisseStatement1.jpg","type":"image\/jpeg"}],"author":"Pharma Guy","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Pharma Guy","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/fda-reads-my-blog-declares-latisse-web\/","url":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/fda-reads-my-blog-declares-latisse-web\/","name":"FDA Reads My Blog: Declares Latisse Web Site Misleading - Pharma Marketing Network","isPartOf":{"@id":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#website"},"datePublished":"2009-09-17T13:20:00+00:00","dateModified":"2019-02-21T01:22:37+00:00","author":{"@id":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#\/schema\/person\/763fc249c59c91ce203db612d81a75a1"},"breadcrumb":{"@id":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/fda-reads-my-blog-declares-latisse-web\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/fda-reads-my-blog-declares-latisse-web\/"]}]},{"@type":"BreadcrumbList","@id":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/fda-reads-my-blog-declares-latisse-web\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/"},{"@type":"ListItem","position":2,"name":"FDA Reads My Blog: Declares Latisse Web Site Misleading"}]},{"@type":"WebSite","@id":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#website","url":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/","name":"Pharma Marketing Network","description":"Pharma Marketing Network","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#\/schema\/person\/763fc249c59c91ce203db612d81a75a1","name":"Pharma Guy","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#\/schema\/person\/image\/","url":"http:\/\/2.gravatar.com\/avatar\/87853617a5e31233716811d09cdefdf7?s=96&d=identicon&r=g","contentUrl":"http:\/\/2.gravatar.com\/avatar\/87853617a5e31233716811d09cdefdf7?s=96&d=identicon&r=g","caption":"Pharma Guy"},"description":"Pharmaguy\u2122 is a \u201cconstructive critic\u201d of pharma marketing and publishes commentary on the Pharma Marketing Blog and on Scoop.it.","url":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/author\/ehs-pharmaguy\/"}]}},"_links":{"self":[{"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/posts\/7006"}],"collection":[{"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/comments?post=7006"}],"version-history":[{"count":1,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/posts\/7006\/revisions"}],"predecessor-version":[{"id":9590,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/posts\/7006\/revisions\/9590"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/media\/9589"}],"wp:attachment":[{"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/media?parent=7006"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/categories?post=7006"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/tags?post=7006"},{"taxonomy":"topic","embeddable":true,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/topic?post=7006"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}